MCID: TCL003
MIFTS: 43

T Cell Deficiency

Categories: Immune diseases

Aliases & Classifications for T Cell Deficiency

MalaCards integrated aliases for T Cell Deficiency:

Name: T Cell Deficiency 12 14
T-Lymphocyte Deficiency 69

Classifications:



External Ids:

Disease Ontology 12 DOID:11200
NCIt 47 C27872
UMLS 69 C1333147

Summaries for T Cell Deficiency

MalaCards based summary : T Cell Deficiency, also known as t-lymphocyte deficiency, is related to immunodeficiency 7, tcr-alpha/beta deficient and digeorge syndrome. An important gene associated with T Cell Deficiency is CD247 (CD247 Molecule), and among its related pathways/superpathways are Akt Signaling and Phospholipase-C Pathway. The drugs Mycophenolate mofetil and Mycophenolic acid have been mentioned in the context of this disorder. Affiliated tissues include t cells, bone and b cells, and related phenotypes are cellular and endocrine/exocrine gland

Wikipedia : 72 T cell deficiency is a deficiency of T cells, caused by decreased function of individual T cells, it... more...

Related Diseases for T Cell Deficiency

Diseases related to T Cell Deficiency via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 86)
id Related Disease Score Top Affiliating Genes
1 immunodeficiency 7, tcr-alpha/beta deficient 11.0
2 digeorge syndrome 11.0
3 chromosome 10p deletion 10.7
4 immunodeficiency due to defect in mapbp-interacting protein 10.7
5 schimke immunoosseous dysplasia 10.7
6 severe combined immunodeficiency, t cell-negative, b-cell/natural killer-cell positive 10.5 IL7R PTPRC
7 coronin-1a deficiency 10.3 CD3G PTPRC
8 cd40 ligand deficiency 10.3 CD3G PTPRC
9 cd3gamma deficiency 10.2 CD3G ZAP70
10 cd3delta deficiency 10.1 PTPRC ZAP70
11 opitz-kaveggia syndrome 10.0 IL2 IL7R
12 orofaciodigital syndrome iv 9.9 IL2 LRBA PTPRC
13 immunodeficiency 11a 9.9 IL2 ZAP70
14 advanced sleep phase syndrome, familial, 1 9.8 IL2 IL7R PTPRC
15 mucositis 9.8
16 ovarian endometrioid cystadenoma 9.7 IL2 LRBA
17 severe combined immunodeficiency 9.7
18 common variable immunodeficiency 9.7
19 obesity 9.7
20 hepatitis 9.7
21 lupus erythematosus 9.6
22 systemic lupus erythematosus 9.6
23 hyper ige syndrome 9.6
24 hematopoietic stem cell transplantation 9.6
25 hemolytic anemia 9.6
26 autoimmune hemolytic anemia 9.6
27 silicosis 9.5 IL2 IL7R PTPRC ZAP70
28 ataxia-telangiectasia 9.5
29 hepatitis b 9.5
30 adult-onset still's disease 9.5
31 influenza 9.5
32 leukemia 9.5
33 sclerosing cholangitis 9.5
34 herpes simplex 9.5
35 neutropenia 9.5
36 candidiasis 9.5
37 vasculitis 9.5
38 fabry disease 9.5
39 hepatitis c 9.5
40 adult t-cell leukemia 9.5
41 spinal cord injury 9.5
42 chronic mucocutaneous candidiasis 9.5
43 molluscum contagiosum 9.5
44 alopecia 9.5
45 lissencephaly 9.5
46 b cell deficiency 9.5
47 cholangitis 9.5
48 arthritis 9.5
49 rheumatic heart disease 9.5
50 endometriosis 9.5

Graphical network of the top 20 diseases related to T Cell Deficiency:



Diseases related to T Cell Deficiency

Symptoms & Phenotypes for T Cell Deficiency

MGI Mouse Phenotypes related to T Cell Deficiency:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 9.96 CD247 CD3G FOXN1 IL2 IL7R JAGN1
2 endocrine/exocrine gland MP:0005379 9.76 CD247 CD3G FOXN1 IL2 IL7R PTPRC
3 hematopoietic system MP:0005397 9.7 CD247 CD3G FOXN1 IL2 IL7R JAGN1
4 immune system MP:0005387 9.36 FOXN1 IL2 IL7R JAGN1 LRBA PTPRC

Drugs & Therapeutics for T Cell Deficiency

Drugs for T Cell Deficiency (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 388)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Mycophenolate mofetil Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2 128794-94-5 5281078
2
Mycophenolic acid Approved Phase 4,Phase 3,Phase 1,Phase 2 24280-93-1 446541
3
Emtricitabine Approved, Investigational Phase 4,Phase 3,Phase 2 143491-57-0 60877
4
Lopinavir Approved Phase 4,Phase 3,Phase 2 192725-17-0 92727
5
Ritonavir Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 155213-67-5 392622
6
Darunavir Approved Phase 4,Phase 2 635728-49-3, 206361-99-1 213039
7
Lamivudine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 134678-17-4 60825
8
Zidovudine Approved Phase 4,Phase 3,Phase 2,Phase 1 30516-87-1 35370
9
Nevirapine Approved Phase 4,Phase 3,Phase 2,Phase 1 129618-40-2 4463
10
Etravirine Approved Phase 4 269055-15-4 193962
11
Efavirenz Approved, Investigational Phase 4,Phase 3,Phase 2 154598-52-4 64139
12
Aminosalicylic Acid Approved Phase 4 65-49-6 4649
13
Ganciclovir Approved, Investigational Phase 4 82410-32-0 3454
14
Valganciclovir Approved, Investigational Phase 4 175865-60-8 64147
15
Maraviroc Approved, Investigational Phase 4,Phase 2,Phase 3 376348-65-1 3002977
16
Tipranavir Approved, Investigational Phase 4 174484-41-4 65027
17
Altretamine Approved Phase 4 645-05-6 2123
18
Abacavir Approved, Investigational Phase 4,Phase 3,Phase 2 136470-78-5 65140 441300
19
Indinavir Approved Phase 4,Phase 3,Phase 2,Phase 1 150378-17-9 5362440
20
Midazolam Approved, Illicit Phase 4 59467-70-8 4192
21
Saquinavir Approved, Investigational Phase 4 127779-20-8 60787
22
Cobicistat Approved Phase 4,Phase 2 1004316-88-4
23 Dolutegravir Approved Phase 4,Phase 2 1051375-16-6 54726191
24
Cholecalciferol Approved, Nutraceutical Phase 4,Phase 3,Phase 2,Phase 1 67-97-0 6221 10883523 5280795
25
Ergocalciferol Approved, Nutraceutical Phase 4,Phase 3,Phase 2,Phase 1 50-14-6 5280793
26
Vitamin D Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 1406-16-2
27
Pyridoxal Approved, Nutraceutical Phase 4 66-72-8 1050
28
Pyridoxine Approved, Nutraceutical, Vet_approved Phase 4 65-23-6 1054
29
Lactitol Investigational Phase 4,Phase 1,Phase 2 585-86-4 3871
30 Immunosuppressive Agents Phase 4,Phase 2,Phase 3,Phase 1
31 Anti-HIV Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
32 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
33 Anti-Retroviral Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
34 Antiviral Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
35 Cytochrome P-450 CYP3A Inhibitors Phase 4,Phase 3,Phase 2,Phase 1
36 Cytochrome P-450 Enzyme Inhibitors Phase 4,Phase 3,Phase 2,Phase 1
37 Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination Phase 4,Phase 3,Phase 2
38 HIV Protease Inhibitors Phase 4,Phase 3,Phase 2,Phase 1
39 Nucleic Acid Synthesis Inhibitors Phase 4,Phase 3,Phase 2,Phase 1
40
protease inhibitors Phase 4,Phase 3,Phase 2,Phase 1
41 Reverse Transcriptase Inhibitors Phase 4,Phase 3,Phase 2,Phase 1
42
Tenofovir Phase 4,Phase 3,Phase 2 147127-20-6 464205
43 HIV Integrase Inhibitors Phase 4,Phase 2,Phase 3,Early Phase 1
44 Integrase Inhibitors Phase 4,Phase 2,Phase 3,Early Phase 1
45 Raltegravir Potassium Phase 4,Phase 2,Phase 3,Early Phase 1
46 Bone Density Conservation Agents Phase 4,Phase 3,Phase 2,Phase 1
47 Ergocalciferols Phase 4,Phase 3,Phase 2,Phase 1
48 Micronutrients Phase 4,Phase 3,Phase 2,Phase 1
49 Trace Elements Phase 4,Phase 3,Phase 2,Phase 1
50 Vitamins Phase 4,Phase 3,Phase 2,Phase 1

Interventional clinical trials:

(show top 50) (show all 572)

id Name Status NCT ID Phase Drugs
1 Mycophenolate Mofetil in Antiretroviral Naïve Patients 2 (MAN2 Study) Unknown status NCT00120419 Phase 4 mycophenol mofetil (MMF, Cellcept®) 500 mg BID
2 Immune Reconstitution as a Determinant of Adverse Effects to New Antiretroviral Therapy in Persons With Advanced HIV Infection Unknown status NCT00885664 Phase 4 Truvada (tenofovir/emitricitabine);Kaletra (lopinavir/ritonavir)
3 HIV Persistence and Viral Reservoirs Unknown status NCT01025427 Phase 4 Raltegravir, tenofovir/emtricitabine
4 A Post Marketing Survey Study to Evaluate the Safety and Effectiveness of Intelence Completed NCT01741844 Phase 4 No intervention
5 A Post Marketing Survey Study to Evaluate the Safety and Effectiveness of Prezista Completed NCT01741831 Phase 4 No intervention
6 Immunologic Action of a Single Dose Cholecalciferol Completed NCT01845142 Phase 4 single administration of 100.000 I.U. vitamin D;Placebo
7 Immune and Metabolic Effects of Vitamin D Supplementation in Healthy Humans Completed NCT01248442 Phase 4 Cholecalciferol;Placebo
8 An Immunologic Study of Treatment-Naive HIV Patients Starting a Darunavir/Ritonavir- or Efavirenz-Based HAART Completed NCT01541085 Phase 4 Darunavir/Ritonavir (DRV/r);Efavirenz (EFV)
9 Mechanisms of Immune Reconstitution & Reduced Immune Activation Following Darunavir-based ART Completed NCT01869634 Phase 4 darunavir with ritonavir and fixed-dose viread+emtricitabine daily
10 Mesalamine to Reduce T Cell Activation in HIV Infection Completed NCT01090102 Phase 4 Mesalamine (5-aminosalicylic acid, Apriso);Placebo
11 Valganciclovir to Reduce T Cell Activation in HIV Infection Completed NCT00264290 Phase 4 Valganciclovir;Placebo
12 CCR5 Inhibitor Treatment Intensification on CD4+ T-cell Recovery Completed NCT00925756 Phase 4 Maraviroc
13 Induction and Expansion of T Cell Repertoire Using Growth Hormone and Vaccination in HIV-1 Infected Patients Completed NCT00287677 Phase 4 HAART
14 Antiretroviral Therapy Intensification With Raltegravir or Addition of Hyper-immune Bovine Colostrum in HIV-1 Infected Patients With Suboptimal CD4+ T Cell Response Completed NCT00772590 Phase 4 Raltegravir;Hyper-immune Bovine Colostrum;raltegravir and hyper-immune bovine colostrum
15 Raltegravir Intensification in HIV-infected Patients Completed NCT00631449 Phase 4 Raltegravir;Placebo
16 Once-daily Antiretroviral Therapy in HIV-1 Infected Patients With CD4+ Cell Counts Below 100 Cells/Mcl Completed NCT00532168 Phase 4 tenofovir + emtricitabine + efavirenz;tenofovir + emtricitabine + lopinavir-ritonavir;tenofovir + emtricitabine + atazanavir-ritonavir
17 Maraviroc as an Immunomodulatory Drug for Antiretroviral-treated HIV Infected Patients Exhibiting Immunologic Failure Completed NCT00735072 Phase 4 Placebo;Maraviroc
18 Vitamin D Supplementation in Patients With Diabetes Mellitus Type 2 Completed NCT01741181 Phase 4 Vitamin D supplementation;Placebo Pill
19 A Pilot Project of Virologic, Pharmacologic and Immunologic Correlates of Gastrointestinal-Associated Lymphoid Tissue Immune Reconstitution Following Maraviroc Therapy Completed NCT00870363 Phase 4 maraviroc in combination with 2 NRTIs (dual nucleoside reverse transcriptase inhibitor);maraviroc plus raltegravir in combination with 2 NRTIs (dual nucleoside reverse transcriptase inhibitor);efavirenz [or other NNRTI (non-nucleoside reverse transcriptase inhibitor)]
20 Immunogenicity and Safety of Trivalent Influenza Vaccine in Non-pregnant HIV-infected Women Completed NCT01812980 Phase 4
21 A Research Study to See if a Change in Therapy for HIV Infection Can Improve the Immune Response to Treatment Completed NCT00145795 Phase 4 Kaletra + Current Dual NRTI Backbone;Current Regimen
22 Study Of Investigational Regimen Combining FDA Approved HIV Drugs In HIV Subjects Experiencing Early Virologic Failure Completed NCT00038506 Phase 4 abacavir/lamivudine/zidovudine;tenofovir
23 Yoga for the Management of HIV-Metabolic Syndromes Completed NCT00627380 Phase 4
24 Switching Undetectables to Selzentry Completed NCT01866267 Phase 4 Maraviroc
25 Maraviroc in Immunological Non-Responder (INR) HIV-1-infected Subjects Completed NCT00884858 Phase 4 Maraviroc
26 Intermittent Versus Continuous Medication in the Treatment of HIV Completed NCT00001967 Phase 4 HAART
27 Influence of the MDR1 Genotype on Blood Levels of Indinavir and Saquinavir in Healthy Volunteers Completed NCT00050180 Phase 4 Midazolam;Indinavir;Saquinavir
28 Vaccine Responses to Influenza A H1N1/09 Immunization in High-risk Patients Completed NCT01022905 Phase 4
29 Strategies of Interruption/Reinitiation of Antiretroviral Therapy in HIV-Infected Patients With Lipodystrophy Completed NCT00646984 Phase 4 Standard continuous antiretroviral therapy;CD-4 guided therapy interruption;Viral load driven treatment interruption
30 VENICE Study Nevirapine Full Dose/Dose Escalation Completed NCT00704249 Phase 4 nevirapine;nevirapine
31 Immune Recovery in Advanced , ARV-naïve, HIV-1-infected Individuals Taking Dolutegravir or Ritonavir-boosted Darunavir Recruiting NCT02337322 Phase 4 Dolutegravir;Darunavir/r
32 Identification of New Immune Factors Specific of Relapse in Childhood B Lineage Acute Lymphoblastic Leukemia Recruiting NCT02618109 Phase 4
33 Optimization of Darunavir Therapy and Dosage Recommendations Recruiting NCT03101644 Phase 4 Darunavir
34 Immediate Initiation of Antiretroviral Therapy During "Hyperacute" HIV Infection Recruiting NCT02656511 Phase 4 Dolutegravir;Emtricitabine/Tenofovir
35 Modulation of Monocyte Activation by Atorvastatin in HIV Infection Active, not recruiting NCT01263938 Phase 4 Atorvastatin
36 Downmodulating Monocyte Activation for HIV-1 Associated Neurocognitive Disorders (HAND) Active, not recruiting NCT01600170 Phase 4 Atorvastatin (generic Lipitor);placebo
37 Evaluation of Safety and Immunogenicity of a Human Papillomavirus (HPV) Vaccine in Human Immunodeficiency Virus (HIV) Infected Females Active, not recruiting NCT01031069 Phase 4
38 MP Diagnostics HTLV Blot 2.4 Post-Market Clinical Study Active, not recruiting NCT03226119 Phase 4
39 Immunodeficiency in Cartilage-hair Hypoplasia: Sub-project on Safety of Vaccination Against Chickenpox Enrolling by invitation NCT02383797 Phase 4
40 Optimization of Antiretroviral Therapy Not yet recruiting NCT02935075 Phase 4 Tenofovir disoproxil;Lamivudine;Efavirenz
41 Triumeq As an Integrase Single Tablet Regimen in People With HIV Who Inject Drugs Not yet recruiting NCT02659761 Phase 4 dolutegravir/abacavir/lamivudine
42 Immune Reconstitution of Lopinavir/Ritonavir-Based vs Efavirenz-based HAART in Advanced HIV Disease Terminated NCT00775606 Phase 4 Lopinavir 400 mg/ritonavir 100 mg;Efavirenz
43 Raltegravir (Isentress/MK-0518) and HIV-1 Infected CD4 Cells During Acute/Early HIV-1 Terminated NCT00781287 Phase 4 3-drug anti-HIV therapy;Raltegravir
44 Prevention of Early Mortality by Presumptive Tuberculosis (TB) Treatment Terminated NCT01417988 Phase 4 Experimental: Empiric TB treatment;ART only arm
45 Evaluation of 3TC or FTC Mono-therapy Compared to Continuing HAART as a Bridging Strategy Terminated NCT01338025 Phase 4 HAART regimen;3TC or FTC monotherapy
46 T-Cell Depletion and Stem Cell Transplant for Immune Deficiencies and Histiocytic Disorders Unknown status NCT00176826 Phase 2, Phase 3 Myeloablative conditioning regimen
47 Early cART and cART in Combination With Autologous HIV-1 Specific Cytotoxic T Lymphocyte (CTL) Infusion in The Treatment of Acute HIV-1 Infected Adults Unknown status NCT02231281 Phase 3 cART(TDF/AZT+3TC+LPV/r)
48 Effect on Liver Histology of Vitamin D in Patients With Non-alcoholic Steatohepatitis Unknown status NCT01623024 Phase 3 Vitamin D
49 The Use of Nutropin Depot in HIV-Infected Adult Males Unknown status NCT00286676 Phase 2, Phase 3 Nutropin
50 Low-Dose Leptin and the Formerly-Obese Unknown status NCT00073242 Phase 3 Leptin;T3 repletion

Search NIH Clinical Center for T Cell Deficiency

Genetic Tests for T Cell Deficiency

Anatomical Context for T Cell Deficiency

MalaCards organs/tissues related to T Cell Deficiency:

39
T Cells, Bone, B Cells, Testes, Bone Marrow, Liver, Kidney

Publications for T Cell Deficiency

Articles related to T Cell Deficiency:

(show top 50) (show all 123)
id Title Authors Year
1
Expansion of cytotoxic CD56(bright) natural killer cells during T-cell deficiency after allogeneic hematopoietic stem cell transplantation. ( 28778795 )
2017
2
Roles of Aluminum Hydroxide and Monophosphoryl Lipid A Adjuvants in Overcoming CD4+ T Cell Deficiency To Induce Isotype-Switched IgG Antibody Responses and Protection by T-Dependent Influenza Vaccine. ( 27881702 )
2017
3
Both mucosal-associated invariant and natural killer T-cell deficiency in multiple myeloma can be countered by PD-1 inhibition. ( 28385777 )
2017
4
Peripheral invariant natural killer T cell deficiency in metabolically unhealthy but normal weight versus metabolically healthy but obese individuals. ( 28322093 )
2016
5
T cell deficiency in spinal cord injury: altered locomotor recovery and whole-genome transcriptional analysis. ( 26546062 )
2015
6
Mucosal-Associated Invariant T Cell Deficiency in Chronic Obstructive Pulmonary Disease. ( 26552490 )
2015
7
Hypomorphic interleukin-7 receptor I+-chain mutations and T-cell deficiency: a delay in diagnosis. ( 26123418 )
2015
8
Regulatory T-cell deficiency and immune dysregulation, polyendocrinopathy, enteropathy, X-linked-like disorder caused by loss-of-function mutations in LRBA. ( 25468195 )
2015
9
Invariant natural killer T cell deficiency leads to the development of spontaneous liver inflammation dependent on I^I'T cells in mice. ( 25791517 )
2015
10
Invariant Natural Killer T Cell Deficiency and Functional Impairment in Sleep Apnea: Links to Cancer Comorbidity. ( 26414901 )
2015
11
Syndrome of selective IgM deficiency with severe T cell deficiency associated with disseminated cutaneous mycobacterium avium intracellulaire infection. ( 26550546 )
2015
12
Interleukin-7 signalling defects in naive CD4+ T cells of HIV patients with CD4+ T-cell deficiency on antiretroviral therapy are associated with T-cell activation and senescence. ( 24499954 )
2014
13
Additional B-cell deficiency does not affect growth and angiogenesis of ectopic human endometrium in T-cell-deficient endometriosis mouse models during long-term culture. ( 25270508 )
2014
14
Blood dendritic cell levels associated with impaired IL-12 production and T-cell deficiency in patients with kidney disease: implications for post-transplant viral infections. ( 24963818 )
2014
15
Mucosal-associated invariant T cell deficiency in systemic lupus erythematosus. ( 25225673 )
2014
16
Attenuated adipose tissue and skeletal muscle inflammation in obese mice with combined CD4+ and CD8+ T cell deficiency. ( 24530773 )
2014
17
Regulatory T-cell deficiency in rheumatic heart disease: a preliminary observational study. ( 23610999 )
2013
18
The protective effects of T cell deficiency against brain injury are ischemic model-dependent in rats. ( 23228347 )
2013
19
Impaired spatial memory in mice lacking CD3IP is associated with altered NMDA and AMPA receptors signaling independent of T-cell deficiency. ( 24259588 )
2013
20
Combined B- and T-cell deficiency does not protect against obesity-induced glucose intolerance and inflammation. ( 23478176 )
2013
21
Fine-tuning of regulatory T cell function: the role of calcium signals and naive regulatory T cells for regulatory T cell deficiency in multiple sclerosis. ( 23576680 )
2013
22
VI'2 T cell deficiency in granulomatosis with polyangiitis (Wegener's granulomatosis). ( 23891739 )
2013
23
CD8 T cell deficiency impairs control of Epstein--Barr virus and worsens with age in multiple sclerosis. ( 21791511 )
2012
24
Natural killer T cell deficiency in active adult-onset Still's Disease: correlation of deficiency of natural killer T cells with dysfunction of natural killer cells. ( 22605480 )
2012
25
Enzyme replacement therapy partially prevents invariant Natural Killer T cell deficiency in the Fabry disease mouse model. ( 22425450 )
2012
26
CD8+ T-Cell Deficiency, Epstein-Barr Virus Infection, Vitamin D Deficiency, and Steps to Autoimmunity: A Unifying Hypothesis. ( 22312480 )
2012
27
Ruling out HIV infection when testing for severe combined immunodeficiency and other T-cell deficiencies. ( 22386446 )
2012
28
T cell deficiency does not reduce lesions in mice produced by intracerebral injection of NMO-IgG and complement. ( 21492943 )
2011
29
CD4+ T-cell deficiency in HIV patients responding to antiretroviral therapy is associated with increased expression of interferon-stimulated genes in CD4+ T cells. ( 22006994 )
2011
30
IL-15 ex vivo overcomes CD4+ T cell deficiency for the induction of human antigen-specific CD8+ T cell responses. ( 21474552 )
2011
31
Lung metastasis fails in MMTV-PyMT oncomice lacking S100A4 due to a T-cell deficiency in primary tumors. ( 20103644 )
2010
32
Profound invariant natural killer T-cell deficiency in inflammatory arthritis. ( 20444757 )
2010
33
A multiplex immunoassay using the Guthrie specimen to detect T-cell deficiencies including severe combined immunodeficiency disease. ( 20660143 )
2010
34
Consequences of increased CD45RA and RC isoforms for TCR signaling and peripheral T cell deficiency resulting from heterogeneous nuclear ribonucleoprotein L-like mutation. ( 20505149 )
2010
35
Skin inflammation arising from cutaneous regulatory T cell deficiency leads to impaired viral immune responses. ( 20548030 )
2010
36
Can T-cell deficiency affect spatial learning ability following toluene exposure? ( 19923859 )
2010
37
Hematopoietic stem cell transplantation for profound T-cell deficiency (combined immunodeficiency). ( 20493397 )
2010
38
Functional T-cell deficiency in adolescents who experience serogroup C meningococcal disease despite receiving the meningococcal serogroup C conjugate vaccine. ( 20463106 )
2010
39
Newborn screening for T-cell deficiency. ( 20864885 )
2010
40
Invariant natural killer (iNK) T cell deficiency in patients with common variable immunodeficiency. ( 19664144 )
2009
41
Congenital T cell deficiency in a patient with CHARGE syndrome. ( 19187738 )
2009
42
Common variable immunodeficiency with regulatory T-cell deficiency treated with rapamycin. ( 19230472 )
2009
43
Hepatitis and human bocavirus primary infection in a child with T-cell deficiency. ( 18842946 )
2008
44
Reduced protection from simian immunodeficiency virus SIVmac251 infection afforded by memory CD8+ T cells induced by vaccination during CD4+ T-cell deficiency. ( 18667509 )
2008
45
Generating functional CD8+ T cell memory response under transient CD4+ T cell deficiency: implications for vaccination of immunocompromised individuals. ( 18506880 )
2008
46
The effects of T cell deficiency on the development of worms and granuloma formation in mice infected with Schistosoma japonicum. ( 18246371 )
2008
47
Immunological mechanisms and clinical implications of regulatory T cell deficiency in a systemic autoimmune disorder: roles of IL-2 versus IL-15. ( 18465774 )
2008
48
Adult onset of T-cell deficiency with impaired CD2 expression complicated by Rhodococcus infection: a case report. ( 17378264 )
2007
49
T cell deficiency leads to liver carcinogenesis in azoxymethane-treated rats. ( 16380649 )
2006
50
Inherited and somatic CD3zeta mutations in a patient with T-cell deficiency. ( 16672702 )
2006

Variations for T Cell Deficiency

Expression for T Cell Deficiency

Search GEO for disease gene expression data for T Cell Deficiency.

Pathways for T Cell Deficiency

Pathways related to T Cell Deficiency according to GeneCards Suite gene sharing:

(show all 30)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
13.23 CD247 CD3G IL2 IL7R RHOH ZAP70
2
Show member pathways
12.89 CD247 CD3G IL2 RHOH ZAP70
3
Show member pathways
12.41 CD247 CD3G IL2 ZAP70
4
Show member pathways
12.39 CD247 CD3G IL2 PTPRC ZAP70
5
Show member pathways
12.16 CD247 CD3G PTPRC ZAP70
6
Show member pathways
12.15 CD3G PTPRC ZAP70
7
Show member pathways
11.91 CD247 CD3G IL2 ZAP70
8 11.84 IL2 IL7R PTPRC
9
Show member pathways
11.81 CD247 CD3G IL2
10 11.8 CD247 CD3G ZAP70
11
Show member pathways
11.77 CD247 CD3G IL2 PTPRC ZAP70
12 11.73 IL2 IL7R PTPRC
13 11.68 CD247 CD3G RHOH ZAP70
14 11.65 IL2 IL7R PTPRC
15 11.61 CD247 CD3G PTPRC
16
Show member pathways
11.6 CD247 CD3G
17 11.6 IL2 IL7R PTPRC
18
Show member pathways
11.6 CD247 CD3G PTPRC ZAP70
19 11.58 CD247 CD3G ZAP70
20 11.55 CD247 CD3G ZAP70
21
Show member pathways
11.49 CD247 CD3G PTPRC ZAP70
22
Show member pathways
11.46 CD247 CD3G IL2
23
Show member pathways
11.4 CD247 CD3G IL2 PTPRC ZAP70
24 11.35 CD247 CD3G ZAP70
25 11.18 CD247 CD3G
26 11.15 IL2 ZAP70
27 11.12 IL2 ZAP70
28 11.11 IL7R PTPRC ZAP70
29 11.04 CD247 IL2
30 10.94 CD247 CD3G IL2

GO Terms for T Cell Deficiency

Cellular components related to T Cell Deficiency according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 immunological synapse GO:0001772 9.16 RHOH ZAP70
2 alpha-beta T cell receptor complex GO:0042105 8.96 CD247 CD3G
3 T cell receptor complex GO:0042101 8.8 CD247 CD3G ZAP70

Biological processes related to T Cell Deficiency according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 immune response GO:0006955 9.73 IL2 IL7R PNP ZAP70
2 cell surface receptor signaling pathway GO:0007166 9.67 CD247 CD3G IL7R PTPRC
3 positive regulation of B cell proliferation GO:0030890 9.48 IL2 PTPRC
4 B cell proliferation GO:0042100 9.46 IL7R PTPRC
5 positive regulation of T cell proliferation GO:0042102 9.43 IL2 PNP PTPRC
6 positive regulation of T cell differentiation GO:0045582 9.4 IL2 ZAP70
7 positive regulation of alpha-beta T cell differentiation GO:0046638 9.32 PNP ZAP70
8 T cell receptor signaling pathway GO:0050852 9.26 CD247 CD3G PTPRC ZAP70
9 negative regulation of T cell mediated cytotoxicity GO:0001915 9.16 IL7R PTPRC
10 T cell differentiation GO:0030217 9.02 IL2 IL7R PTPRC RHOH ZAP70

Sources for T Cell Deficiency

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....